CAS: 2157-19-9 - Endodiol
Formula:C9H8Cl6O2
InChI:InChI=1S/C9H8Cl6O2/c10-5-6(11)8(13)4(2-17)3(1-16)7(5,12)9(8,14)15/h3-4,16-17H,1-2H2
InChI key:InChIKey=GTSJHTSVFKEASK-UHFFFAOYSA-N
SMILES:ClC1=C(Cl)C2(Cl)C(CO)C(CO)C1(Cl)C2(Cl)Cl
- Synonyms:
- 5-Norbornene-2,3-dimethanol, 1,4,5,6,7,7-hexachloro-
- Bicyclo[2.2.1]hept-5-ene-2,3-dimethanol, 1,4,5,6,7,7-hexachloro-
- 1,4,5,6,7,7-Hexachloro-2,3-bis(hydroxymethyl)-5-norbornene
- 1,4,5,6,7,7-Hexachlorobicyclo[2.2.1]hept-5-ene-2,3-dimethanol
- Thiodandiol
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | Endosulfan-alcohol REF: 04-C13130000CAS: 2157-19-9 | - - - | 126.00 € | Wed 22 Jan 25 |
 | Endosulfandiol REF: TR-E555518CAS: 2157-19-9 | - - - | 237.00 €~1,576.00 € | Mon 03 Mar 25 |
 | ENDOSULFAN ALCOHOL REF: IN-DA00BBL7CAS: 2157-19-9 | - - - | - - - | Discontinued product |
 | Endosulfan alcohol REF: 3D-CAA15719CAS: 2157-19-9 | Min. 95% | - - - | Discontinued product |
Endosulfan-alcohol
CAS:2157-19-9
Formula:
C9H8Cl6O2
Color and Shape:
Off White Crystalline Powder
Molecular weight:
360.88
Ref: 04-C13130000
| 100mg | 126.00 € |
Estimated delivery in United States, on Wednesday 22 Jan 2025
Endosulfandiol
Controlled ProductCAS:2157-19-9
Applications Endosulfandiol is a metabolite of Endosulfan (E555505), an insecticide that poses health risks to …
Formula:
C9H8Cl6O2
Color and Shape:
Neat
Molecular weight:
360.88
Ref: TR-E555518
| 50mg | 237.00 € | ||
| 250mg | 1,007.00 € | ||
| 500mg | 1,576.00 € |
Estimated delivery in United States, on Monday 3 Mar 2025
Ref: IN-DA00BBL7
| 100mg | Discontinued | Request information |
Endosulfan alcohol
CAS:2157-19-9
Endosulfan is a chlorinated insecticide that has been shown to be carcinogenic in vivo and …
Formula:
C9H8Cl6O2
Purity:
Min. 95%
Molecular weight:
360.88 g/mol
Ref: 3D-CAA15719
| 25mg | Discontinued | Request information | |
| 50mg | Discontinued | Request information | |
| 100mg | Discontinued | Request information | |
| 250mg | Discontinued | Request information | |
| 500mg | Discontinued | Request information |
